BMS - Consensus statement

Post Reprod Health. 2018 Sep;24(3):133-138. doi: 10.1177/2053369118795349.

Abstract

Urogenital atrophy is more common than it would first appear and women do not always seek advice and guidance. Confusion still exists between systemic hormone replacement therapy (HRT) and local estrogen preparations but new treatment modalities have emerged that extend the range of options beyond lubricants, moisturisers and vaginal estrogen preparations.

Keywords: dryness dyspareunia; genito-urinary syndrome of menopause (GSM); non-hormonal ubricants and moisturisers; pruritus; sexual dysfunction; urogenital atrophy; vaginal soreness; vulvovaginal atrophy.

Publication types

  • Practice Guideline

MeSH terms

  • Atrophy / diagnosis
  • Atrophy / etiology
  • Atrophy / therapy
  • Consensus
  • Estrogen Replacement Therapy
  • Female
  • Humans
  • Laser Therapy
  • Lubricants / therapeutic use
  • Selective Estrogen Receptor Modulators / therapeutic use
  • Sexuality
  • Tamoxifen / analogs & derivatives
  • Tamoxifen / therapeutic use
  • Vagina / pathology*
  • Vulva / pathology*

Substances

  • Lubricants
  • Selective Estrogen Receptor Modulators
  • Tamoxifen
  • Ospemifene